This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Development and safety of PI3K inhibitors in cancer
Archives of Toxicology Open Access 11 February 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original article
Matasar, M. J. et al. Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. https://doi.org/10.1016/S1470-2045(21)00145-5 (2021)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Killock, D. Copanlisib safe and active in combination. Nat Rev Clin Oncol 18, 322 (2021). https://doi.org/10.1038/s41571-021-00512-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-021-00512-1
This article is cited by
-
An injectable subcutaneous colon-specific immune niche for the treatment of ulcerative colitis
Nature Biomedical Engineering (2023)
-
Development and safety of PI3K inhibitors in cancer
Archives of Toxicology (2023)